Form 4: Tandem Diabetes Care Executive Susan Morrison Reports Stock Transactions

EVP & Chief Admin. Officer Susan Morrison reports acquisition and disposal of Tandem Diabetes Care stock and derivative securities.

Summary

• Susan Morrison, EVP & Chief Admin. Officer of Tandem Diabetes Care, filed a Form 4 detailing changes in beneficial ownership.
• On May 28, 2024, she acquired 406 shares of common stock through the vesting of restricted stock units (RSUs) at $0 per share.
• Also on May 28, 2024, 117 shares were withheld to satisfy tax obligations at a price of $51.73 per share.
• Following these transactions, Morrison directly owns 21,845 shares of Tandem Diabetes Care common stock.
• On May 23, 2024, Morrison was awarded 13,161 restricted stock units (RSUs) and 13,160 performance stock units (PSUs) under the 2023 Long-Term Incentive Plan.
• The RSUs vest over time, while the PSUs vest based on the achievement of pre-defined performance metrics as of December 31, 2026.
• Morrison also has 406 restricted stock units that vested on May 28, 2024, from a previous grant in 2020.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The granting of RSUs and PSUs is a positive sign, but the withholding of shares for taxes is a neutral event.

Positives

• The granting of RSUs and PSUs to a key executive signals continued alignment of interests with shareholders.
• The vesting of RSUs indicates that previous performance milestones have been met.

Negatives

• The withholding of shares for tax obligations, while standard, reduces the executive's net share gain.

Risks

• The vesting of PSUs is contingent on achieving specific performance metrics by December 31, 2026; failure to meet these metrics could result in no shares vesting.
• The value of the shares is subject to market fluctuations, which could impact the overall value of the vested RSUs and PSUs.

Future Outlook

The vesting of RSUs and PSUs is subject to continued service and, in the case of PSUs, the achievement of performance metrics by December 31, 2026.

Industry Context

Executive stock transactions are common in the healthcare industry and are used to incentivize and retain key personnel. The vesting schedules and performance-based awards are typical components of executive compensation packages.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry often include a mix of salary, stock options, restricted stock units, and performance-based bonuses.
• Companies like Insulet and Dexcom also utilize similar long-term incentive plans to align executive interests with shareholder value.
• The vesting schedules for RSUs and PSUs are generally in line with industry standards, typically ranging from three to five years.

Stakeholder Impact

• The granting of RSUs and PSUs can positively impact shareholder confidence by aligning executive interests with company performance.
• Employees may be indirectly impacted by the performance metrics tied to the PSUs, as these metrics likely reflect broader company goals.

Key Dates